



Figure S1 The detail of criteria regarding the modifying treatment schedule.

Table S1 Prior chemotherapy regimens of the 1st line (n=65)

Histology	Regimens	N	%
Adenocarcinoma (n=43)	Pemetrexed-contained regimen (n=36)		
	Cisplatin + pemetrexed	7	10.8
	Cisplatin + pemetrexed + bevacizumab	14	21.5
	Cisplatin + pemetrexed + bevacizumab + erlotinib	1	1.5
	CBDCA + pemetrexed	5	7.7
	CBDCA + pemetrexed + bevacizumab	7	10.8
	CBDCA + pemetrexed + gefitinib	1	1.5
	Pemetrexed + bevacizumab	1	1.5
	Others (n=7)		
	Cisplatin + vinorelbine	2	3.1
	CBDCA + gemcitabine	2	3.1
	CBDCA + S1	1	1.5
	DTX	1	1.5
Cisplatin + DTX + thoracic radiotherapy	1	1.5	
Squamous (n=20)	Gemcitabine-contained regimen (n=7)		
	Cisplatin + gemcitabine	6	9.2
	Gemcitabine	1	1.5
	Others (n=13)		
	Cisplatin + S1	1	1.5
	CBDCA + S1	7	10.8
	DTX	2	3.1
Vinorelbine	2	3.1	
Cisplatin + DTX + thoracic radiotherapy	1	1.5	
Adenosquamous (n=2)	Cisplatin + DTX + thoracic radiotherapy	1	1.5
	CBDCA + thoracic radiotherapy	1	1.5

CBDCA, carboplatin; DTX, docetaxel.

**Table S2** Prior chemotherapy regimens of the 2nd line (n=24)

Histology	Regimens	N	%
Adenocarcinoma (n=16)	Pemetrexed-contained regimen (n=5)		
	CBDCA + pemetrexed	1	4.2
	CBDCA + pemetrexed + bevacizumab	2	8.3
	Pemetrexed	1	4.2
	Others (n=12)		
	CBDCA + gemcitabine	1	4.2
	DTX	8	33.3
Squamous (n=6)	S1	3	12.5
	Gemcitabine-contained regimen (n=1)		
	Cisplatin + gemcitabine	1	4.2
	Others (n=5)		
	CBDCA + S1	2	3.1
Adenosquamous (n=2)	S1	2	3.1
	DTX	1	4.2
	CBDCA + pemetrexed	1	4.2
	Pemetrexed + bevacizumab	1	4.2

CBDCA, carboplatin; DTX, docetaxel.

**Table S3** Subgroup analysis of prognostic factors for ORR and PFS

Characteristics	N (n=65)	ORR (%)			Median PFS (months)			HR (95% CI)
		ORR (%)	95% CI	P value	Median PFS	95% CI	P value	
Histology				0.4899			0.0346	1.774 (1.033–3.045)
Squamous	20	25.0	4.2–45.8		1.7	1.4–3.7		
Non-squamous	45	15.6	4.5–26.6		3.8	2.9–4.5		
Prior DTX treatment				0.2672			0.9512	0.982 (0.548–1.7592)
Yes	15	6.7	0–21.0		3.1	1.3–6.0		
No	50	22	10.1–33.9		3.7	2.0–4.1		
PEM treatment				0.0952			0.1141	0.661 (0.393–1.110)
Yes	42	30.4	10.1–50.8		3.7	2.6–4.4		
No	23	11.9	1.7–22.1		2	1.6–4.0		
Prior gemcitabine treatment				0.0235			0.3077	0.826 (0.418–1.631)
Yes	11	45.5	10.4–80.5		4.0	0.9–5.6		
No	54	13.0	3.7–22.2		3.2	2.0–3.8		
Driver mutation				0.3762			0.0832	1.105 (0.559–2.183)
Yes	10	30.0	0–64.6		2.7	1.2–7.2		
No	55	16.4	6.3–26.5		3.6	2.0–4.1		

ORR, overall response rate; PFS, progression-free survival; DTX, docetaxel; PEM, prior pemetrexed; HR, hazard ratio; CI, confidence interval.